In praise of the CE marking, but medtech’s worst fear is still alive
This article was originally published in Clinica
The European Medicines Agency review meeting, in London last week, passed with scarcely a mention of devices and diagnostics.
You may also be interested in...
As the UK enters the final week of its 47-year membership of the EU, UK medtech industry and commentators look ahead to the routes beyond Brexit for the UK, and a likely intense and often rocky 11 months of trade deal negotiations with EU and global partners. This article is part one of two.
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.
Point-of-care/near-patient testing has been “two years away from major breakthrough” for at least two decades, but fast access to data via automation and IT means that progress might change at last. How the tests are paid for remains an issue. The future of POC was the theme of an investor discussion at the first DxPx conference, held during the Medica 2019 event in Germany.